Company Epistem Plc
TIDM EHP.L (AIM)
Headline Pre-Close Trading Update
Released 22nd July: 7.00am UK
Epistem Holdings Plc
("Epistem" or "the Company")
Pre-Close Trading Update
Epistem (AIM: EHP), the personalised medicine and biotechnology company, today announces a pre-close trading statement for the year ended 30th June 2014.
Income over the full year remained solid and broadly in line with market expectations, with EBITDA losses expected to be around £2.5m reflecting the growing expenditure in preparation for launch of the Company's first product Genedrive®. Net cash at 30th June 2014 was £4.2m.
The Company expects to release its final results for the year ended 30th June 2014 on Tuesday 28th October 2014 and will hold an analysts' meeting on the day.
For further information contact:
Epistem Plc
Matthew Walls, Chief Executive Officer ++44 161 606 7258
John Rylands, Chief Financial Officer
Peel Hunt LLP
James Steel ++44 207 418 8900
Clare Terlouw
Walbrook PR
Mike Wort ++44 207 933 8780
Anna Dunphy
Notes for editors
Please see http://www.epistem.co.uk for additional information
About Epistem:
Epistem is a personalised medicine and biotechnology company commercialising its expertise in adult stem cells in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative diagnostics and biomarkers (Genedrive®), target discovery therapeutics and contract research services for drug development companies. Epistem operates three divisions, Personalised Medicine (Diagnostics and Biomarkers), Contract Research Services and Novel Therapies.